rs8111930 — MRPL4 MRPL4 Atopy-Associated Intronic Variant

Intronic variant in MRPL4 on chromosome 19p13.2 that alters transcription factor binding (AREB6 loss, CREB2 gain), reducing mitochondrial ribosomal protein L4 expression and increasing susceptibility to atopy and allergic rhinitis via the HIF-1α signalling pathway

See your personal result for MRPL4

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

MRPL4 rs8111930 — A Mitochondrial Regulator in the Allergic Pathway

Most people carry the common G allele at rs8111930 — the majority genotype — yet it is also the allele that marginally tips the immune balance toward atopic sensitisation. This variant sits in an intron of MRPL411 MRPL4
Mitochondrial Ribosomal Protein L4, a nuclear-encoded component of the 39S large subunit of the mitochondrial ribosome; required for translation of the 13 proteins encoded in mitochondrial DNA, located on chromosome 19p13.2 near the gene for ICAM-122 ICAM-1
intercellular adhesion molecule-1, a surface protein on endothelial cells and immune cells that mediates cell-cell adhesion during inflammatory responses; soluble ICAM-1 levels are elevated in allergic rhinitis. The minor A allele (~9% globally) is protective against atopy; the common G allele confers modestly elevated risk.

The Mechanism

Although rs8111930 lies within an intron and does not change the MRPL4 protein sequence, in silico transcription factor binding site analysis33 in silico transcription factor binding site analysis
computational prediction of DNA–protein binding motifs using position weight matrices from known transcription factor binding data shows that the A→G substitution has two consequences: (1) loss of a binding site for AREB644 AREB6
Atp1a1 regulatory element binding factor 6, also known as ZEB1/ZFHEP; a zinc-finger/homeodomain transcription factor that acts as a negative regulator of IL-2 gene transcription after T-cell activation, and is involved in tissue-specific gene expression and early development, and (2) gain of a new binding site for CREB255 CREB2
cAMP-responsive element binding protein 2, also known as ATF4; activates transcription in response to cAMP signalling and cellular stress.

The net result of the G allele is altered regulation of MRPL4 expression in immune tissues. MRPL4 has been identified as a downstream target of HIF-1α66 HIF-1α
Hypoxia-Inducible Factor 1-alpha, the master transcriptional regulator of the cellular hypoxic response; in myeloid immune cells, HIF-1α controls inflammatory cytokine production and mast cell activation, and is critical in allergen-induced dendritic cell activation. When HIF-1α signalling is altered, immune cell activation thresholds shift — and in the context of allergen exposure, this can promote atopic sensitisation and allergic rhinitis.

The nearby ICAM-1 locus adds a further mechanistic dimension: soluble ICAM-1 regulates nasal allergic reactions, and genetic variation in this chromosomal region is biologically plausible as an atopy modifier.

The Evidence

The primary evidence comes from a genome-wide association study by Andiappan et al.77 Andiappan et al.
Genome-wide association study for atopy and allergic rhinitis in a Singapore Chinese population. PLoS ONE, 2011 that examined 515 atopic cases and 486 controls in a discovery stage, then replicated top findings in a separate cohort of 2,323 atopic cases and 511 controls. rs8111930 in MRPL4 emerged as one of only two SNPs to reach genome-wide significance across both stages: the A allele was associated with 31% reduced odds of atopy (OR=0.69, p=4.46×10⁻⁵ combined) and 38% reduced odds of allergic rhinitis specifically (OR=0.64, p=7.26×10⁻⁵ combined). The consistent direction across discovery and replication phases — with the expected attenuation of effect size between stages (OR 0.50 → 0.78) — is characteristic of a true positive GWAS signal.

Independent support for MRPL4 as an allergic rhinitis susceptibility gene comes from Wei et al.88 Wei et al.
The association between polymorphisms in the MRPL4 and TNF-α genes and susceptibility to allergic rhinitis. PLoS ONE, 2013, which enrolled 414 AR patients and 293 healthy controls from a Han Chinese population in Beijing. Although this study examined a second MRPL4 SNP (rs11668618, not rs8111930), it confirmed the gene's relevance to AR susceptibility and independently reinforced the MRPL4– allergic rhinitis link in a distinct population.

The evidence level is moderate: discovery-replication GWAS with two independent populations, a plausible mechanistic pathway via HIF-1α, but limited functional validation and no large multi-ethnic meta-analyses specifically for this variant.

Practical Actions

The GG genotype (carried by ~83% of the global population) confers modest excess atopy risk via altered MRPL4 transcription regulation. The actionable implications are targeted toward allergen sensitisation management rather than molecular pathway manipulation:

Nasal allergen burden reduction: The rs8111930 risk signal is strongest for allergic rhinitis specifically. In people who carry the GG genotype and develop nasal allergy symptoms, systematic allergen reduction (HEPA filtration, dust-mite covers, pollen avoidance during peak seasons) addresses the specific trait this variant is associated with.

Monitoring for progressing atopic disease: GG carriers with early-onset atopic features (eczema in infancy, food allergy) are at marginally elevated risk for the atopic march — progression to allergic rhinitis and asthma. Early allergen identification and immunotherapy evaluation is more evidence-supported when multiple atopy risk alleles are present.

No pharmacological implication currently: There is no established drug target or supplement with documented evidence for MRPL4-pathway modulation at this variant. Actions are limited to allergen monitoring and sensitisation reduction.

Interactions

rs8111930 × rs2303067 (SPINK5): rs2303067 SPINK5 Lys420Glu is the primary SPINK5 skin barrier variant in the GeneOps catalog. The two variants act through independent pathways: SPINK5/LEKTI operates at the epidermal barrier, while MRPL4/HIF-1α operates in immune cell activation. Carriers of risk alleles at both loci may have additive atopy susceptibility — barrier dysfunction (SPINK5) enabling allergen sensitisation combined with reduced immune regulatory capacity (MRPL4) lowering the threshold for a sustained allergic response. No published study has formally tested this combination.

Genotype Interpretations

What each possible genotype means for this variant.

AA Protective Homozygous Beneficial

Both copies carry the rare protective A allele, associated with reduced atopy and allergic rhinitis susceptibility via favourable MRPL4 regulation

You carry two copies of the protective A allele at rs8111930. This genotype is rare globally (approximately 0.8% of people carry it). The A allele preserves an AREB6 transcription factor binding site in the MRPL4 gene, maintaining normal mitochondrial ribosomal protein expression and supporting the HIF-1α signalling cascade that regulates immune cell activation thresholds. The GWAS evidence shows A allele carriers have approximately 31% lower odds of atopy and 36% lower odds of allergic rhinitis compared to G allele homozygotes. Your genotype is the most protected form at this locus.

AG Partial Risk Carrier Intermediate

One copy of the risk G allele partially reduces the protective effect at this MRPL4 locus, conferring modestly elevated atopy susceptibility

You carry one protective A allele and one risk G allele at rs8111930. This is the second most common genotype globally (approximately 16% of people). The G allele disrupts an AREB6 binding site and creates a CREB2 binding site in MRPL4's intron, altering the gene's transcriptional regulation in immune tissues. With one protective copy, the effect is intermediate. The GWAS data shows an additive model of risk across allele count, so AG heterozygotes sit between the fully protective AA and the higher-risk GG genotype. The absolute excess risk at a single locus with OR~0.69 per A allele is modest, but it contributes to total atopy polygenic burden.

GG Common Risk Homozygous High Risk

Both copies carry the common G allele; the protective AREB6 binding site in MRPL4 is absent on both chromosomes, conferring the highest atopy and allergic rhinitis susceptibility at this locus

The GWAS that identified rs8111930 (Andiappan et al., PLoS ONE 2011) was conducted in a Singapore Chinese cohort and replicated in a separate East Asian population. The effect size (OR=0.69 per A allele in the combined analysis) is moderate for a GWAS hit — stronger than most GWAS signals — and the finding was consistent across both stages, lending credibility. However, replication in non-East-Asian populations has not been published for this specific SNP, and it is possible that the effect size varies across ancestry groups given the large allele frequency differences (A allele: ~29% African, ~12% European, ~8% East Asian by dbSNP/ALFA data — note: the risk G allele is especially dominant in East Asian ancestry, which was the study population). This should be considered when interpreting the result in individuals of non-East-Asian descent.

The mechanistic hypothesis centres on altered MRPL4 regulation affecting mitochondrial function in immune cells, in turn modulating HIF-1α-driven responses to allergens. This is a plausible but not yet functionally validated pathway — the GWAS identified the association, in silico analysis predicted the transcription factor binding change, but direct experimental evidence in human immune cells is not yet published.